Other signatures, including some targetable immune checkpoint components such as indoleamine 2,3-dioxygenase (IDO1), lymphocyte-activation gene 3 (LAG-3), or interferon-gamma (IFNγ) genes can predict benefit from immunotherapy in “colder tumors” such as luminal B BC patients [56,57]. This evidence concerns the gene IFNG and breast cancer.